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The incretin hormones glucagon-like peptide-1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (GIP)
areimportantinbloodglucoseregulation.However,bothin-
cretinhormonesarerapidlydegradedbytheenzymedipep-
tidyl peptidase IV (DPPIV). The concept of DPPIV inhibi-
tionasatreatmentfortype2diabeteswasevaluatedinanew
largeanimalmodelofinsulin-deﬁcientdiabetesandreduced
β-cell mass, the nicotinamide (NIA) (67 mg/kg) and strep-
tozotocin (STZ) (125 mg/kg)–treated minipig, using the
DPPIVinhibitor,valinepyrrolidide(VP)(50mg/kg).VPdid
not signiﬁcantly affect levels of intact GLP-1 but increased
levels of intact GIP (from 4543±1880 to 9208±3267 pM
×min;P<.01),thusimprovingglucosetolerance(areaun-
derthecurve[AUC]forglucosereducedfrom1904±480to
1582±353mM×min;P=.05).VPdidnotincreaseinsulin
levels during the oral glucose tolerance test (OGTT) but in-
creased the insulinogenic index in normal animals (from
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83±42 to 192±108; P<.05), but not after NIA+STZ,
possibly because of less residual insulin secretory capacity
in these animals. GIP seems to contribute to the antihy-
perglycemic effect of VP in this model; however, additional
mechanisms for the effect of DPPIV inhibition cannot be
excluded.TheauthorsconcludethatDPPIVinhibitorsmay
be useful to treat type 2 diabetes, even when this is due to
reduced β-cell mass.
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Theincretinhormonesglucagon-likepeptide-1(GLP-1)and
glucose-dependent insulinotropic polypeptide (GIP) enhance
postprandial insulin secretion in a glucose-dependent manner
[14,53,69].GLP-1increaseslevelsofinsulinmRNA,promotes
insulin biosynthesis [16, 68], and inhibits glucagon secretion
[53], although this may be secondary to GLP-1–induced so-
matostatin secretion [21]. GLP-1 also inhibits gastrointestinal
motility and gastric acid secretion [70, 72], thereby limiting
postprandial glucose excursions, although more recently, di-
rect effects on appetite regulation have been reported [17, 45].
GIP has been indicated to promote glucose uptake in muscle
[51] and fat [52] and has been suggested to increase the afﬁn-
ity of the insulin receptor [61]. These observations gave rise to
the suggestion that GIP may modulate the effects of insulin by
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directly altering target tissue sensitivity to insulin [52], thereby
contributing to the effective uptake of glucose postprandially
[44, 73]. Receptor antagonists have been used to demonstrate
the physiological role of both incretin hormones in the main-
tenance of normal glucose homeostasis [13, 38, 59, 66]; mice
with targeted deletions of either the GLP-1 or the GIP receptor
become glucose intolerant [43, 60], conﬁrming the importance
of both peptides in the regulation of blood glucose.
The insulinotropic effect of GLP-1 is preserved in patients
with type 2 diabetes [14, 22, 46, 47, 65], as are its effects on
glucagon secretion [48] and gastric emptying [71], whereas it
has been suggested that GIP loses its effect in these subjects
[14, 47], possibly because of a defect in the expression of the
GIP receptor [25]. GLP-1 can normalize glucose levels in type
2 diabetic patients [49] and restore insulin secretion towards
normalinimpairedglucosetolerantsubjects[18],meaningthat
the peptide could have considerable therapeutic application.
However, both GLP-1 and GIP are rapidly degraded to ap-
parently inactive metabolites by the enzyme dipeptidyl pepti-
dase IV (DPPIV) [10, 11, 30, 41], although GIP seems less
susceptible to degradation than GLP-1 [9, 10]. Inhibition of
DPPIV is known to protect the biologically active forms of
GLP-1 and GIP from N-terminal breakdown [7, 8], and is a
newly emerging principle for drug treatment of type 2 diabetes
[11, 24]. The rationale for this principle is that by protecting
the endogenous intact forms of the incretin hormones, their
beneﬁcial effects on glucose tolerance will be enhanced. The
approachofenhancinglevelsofintactendogenousincretinhor-
mones by inhibition of DPPIV has been effective in improving
glucose tolerance in several animal models [1, 4, 56, 57, 63]
and has recently been shown to improve metabolic control in
type 2 diabetic humans [2]. However, because the principle
of inhibiting DPPIV relies on an improved incretin effect, this
mightrequirethatfunctionalβ-cellmasshasasufﬁcientcapac-
ity to respond to the insulinotropic effect of increased incretin
levels before an effect on metabolic control is seen. The an-
imal studies used insulin-resistant rodents [1, 4, 56, 57, 63],
whereas the study in human subjects included mildly diabetic
subjects (fasting blood glucose <10 mM) [2]. Whether DPPIV
inhibitionwillbeeffectiveinsubjectswithreducedβ-cellmass
remains to be determined. The aim of the present study was,
therefore,toevaluatetheconceptofDPPIVinhibitionfortreat-
ment of reduced glucose tolerance due to a reduction of β-cell
mass. The model used was a new large-animal model of mild
insulin-deﬁcient diabetes, the nicotinamide (NIA) and strepto-
zotocin (STZ)–treated G¨ ottingen minipig [37]. The G¨ ottingen
minipig was chosen because its size makes it possible to ob-
tain a relatively large number of blood samples, thus making
this species useful in the study of GLP-1 and GIP metabolism.
Furthermore,thepigsharesmanyanatomicalandphysiological
similaritiesofdigestionandmetabolismwiththehuman[6,42,
64] and the G¨ ottingen minipig has been characterized in de-
tail, both with respect to general characteristics such as clinical
chemistry and hematology [15, 19, 29] and, more speciﬁcally,
with respect to glucose and lipid metabolism both in normal
animals [28, 35, 36, 37] and after induction of diabetes [31, 37]
or challenge with high-fat diets [26–28, 36].
MATERIALS AND METHODS
Animals
Six male G¨ ottingen minipigs, obtained from the barrier
unit at Ellegaard G¨ ottingen minipigs ApS, Denmark, 11 to
14 months of age and weighing 25.3 ± 1.4 kg (range 22.8 to
26.8kg)wereused.Theanimalswerehousedinsinglepensun-
der controlled conditions (temperature was kept between 18◦C
and 22◦C, relative air humidity was 30% to 70%, with 4 air
changes per hour), with a 12-hour light:12-hour dark cycle.
The animals were fed a restricted diet, 140 g of SDS minipig
diet (SDS, Essex, England) and 240 g of a commercial swine
fodder(“Svinefoder22”,Slangerup,Denmark),twicedailyand
were allowed free access to water. The pigs were trained care-
fullyinallexperimentalproceduresbeforestartofexperiments.
Animalsservedastheirowncontrolandwerethusstudiedboth
before and after induction of diabetes, with and without dosing
of valine pyrrolidide (VP), a speciﬁc DPPIV inhibitor [50].
The type of study was approved by the Animal Experiments
Inspectorate, Ministry of Justice, Denmark.
Surgical Implantation of Central
Venous Catheters
Two central venous catheters (Certo 455, B. Braun Melsun-
gen AG, Melsungen, Germany) were inserted surgically un-
der general anesthesia as described previously [37]. Postsur-
gical analgesia was maintained by injection of buprenorﬁne,
0.03 mg/kg (Anorﬁn (0.3 mg/mL); GEA, Frederiksberg,
Denmark) and carprofen, 4 mg/kg (Rimadyl vet. (50 mg/mL);
Pﬁzer, Ballerup, Denmark) intramuscularly before the end of
anesthesia and for 3 days post surgery by injection of carpor-
fen, 4 mg/kg once daily intramuscularly. At the start of the
study period, all animals had recovered fully from the sur-
gical procedure as evaluated by normal behavior and eating
patterns.
Mixed-Meal Oral Glucose Tolerance Test
The mixed-meal oral glucose tolerance test (OGTT) was
performedin allanimals1and2weeksbeforeexposuretoNIA
andSTZandwasrepeated2and3weeksafterNIA+STZ.The
test was performed in nonrestrained, freely moving animals inINHIBITION OF DPPIV NORMALIZES GLUCOSE TOLERANCE 95
their home pens to reduce the amount of stress experienced by
the animals during testing.
After an 18-hour overnight fast, animals were dosed in-
travenously with either vehicle (sterile saline (0.9%); SAD,
Copenhagen, Denmark) or VP (50 mg/kg) 15 minutes in ad-
vance of being offered an OGTT of 25 g SDS minipig fodder
and 2 g/kg glucose (500 g/L; SAD). The meal was eaten from
a bowl under supervision. On average it took the pigs 2.5 ±
1.5 minutes (range 1 to 7.5 minutes) to eat the test meal.
Bloodsampleswereobtainedfromthejugularveincatheters
at t =− 30, −20, −1, 7.5( n=3), 15, 30, 45, 60, 90, 120, and
240minutesrelativetothebeginningofingestionoftheglucose
load.
Handling and Analysis of Blood Samples
Three milliliters of full blood was obtained per sample and
was immediately transferred to vials containing EDTA (1.6
mg/mL, ﬁnal concentration), aprotinin 500 kIU/mL full blood
(Trasylol, 10,000 kIU/mL; Bayer, Lyngby, Denmark) and VP
(0.01 mM, ﬁnal concentration, except for plasma for determi-
nation of DPPIV activity, where VP was not added) and kept
on ice until centrifugation. Samples were centrifuged (4◦C,
10 minutes, 3500 rpm), plasma separated, and stored at −20◦C
until analysis. Plasma glucose was analyzed by the hexokinase
method using a Cobas Mira plus autoanalyzer (Roche Diag-
nostic Systems, Basel, Switzerland) following manufacturer’s
instructions. Plasma insulin was analyzed in a 2-site immuno-
metricassaywithmonoclonalantibodiesascatchinganddetect-
ing antibodies (catching antibody HUI-018 raised against the
A-chain of human insulin, detecting antibody OXI-005 raised
against the B-chain of bovine insulin) [3] and using puriﬁed
porcine insulin for calibration of the assay. The minimal de-
tectable concentration was 3.2 pM and the upper limit was
1200 pM (no sample dilution). Inter- and intra-assay variations
at3concentrationlevelswere,respectively,15.3%and3.2%(at
342 pM), 9.9% and 7.6% (at 235 pM), and 14.6% and 4.4% (at
87 pM). Recovery at high-, medium-, and low-concentration
levels was 97.1%, 97.9%, and 101%, respectively. A com-
mercial kit from Linco was used to measure plasma glucagon
(GlucagonRIAkit,cataloguenumberGL-32K)concentrations.
Plasma levels of intact and total incretin hormones were
measured using speciﬁc radioimmunoassays that were vali-
dated by high-performance liquid chromatography (HPLC) as
describedpreviously[9,10].TotalGIPwasmeasuredusingthe
C-terminally directed antiserum R65 [33, 34]. The assay has
a detection limit of <2 pM and an intra-assay variation of ap-
proximately 6%. Intact, biologically active GIP was measured
using a newly developed assay [10]. The assay has a detection
limit of approximately 5 pM, an ED50 of 48 pM, and an intra-
assay variation of <6%. VP (0.01 mM ﬁnal concentration) was
added to the assay buffer to prevent N-terminal degradation of
GIP during the assay incubation. For both assays, human GIP
(Peninsula Laboratories Europe, St Helens, Merseyside, UK)
was used as standard (porcine GIP cross-reacts fully in both
assays) and radiolabeled GIP was from Amersham Pharmacia
Biotech (Little Chalfont, Buckinghamshire, UK).
GLP-1 concentrations were determined using assays di-
rected toward each end of the molecule using human GLP-1
standards. N-terminal immunoreactivity was measured using a
newlydevelopedassayfortheintactN-terminusofGLP-1[12].
The assay has a detection limit of approximately 5 pM and an
ED50 of 80.8 ± 3.4 pM. The assay is speciﬁc for the intact N-
terminus of GLP-1, and cross-reacts <0.1% with GLP-1(9–36)
amide, or with the structurally related peptides GLP-1(1–36)
amide, GIP(1–42), GIP(3–42), GLP-2(1–33), GLP-2(3–33), or
glucagon at concentrations of up to 100 nM. It has a cross-
reactivity of approximately 4% with the major proglucagon
fragment (proglucagon(72–158)) secreted from the pancreas.
Intra-assay variation was <6% and interassay variations were
approximately8%and12%for20and80pMstandards,respec-
tively.VP(0.01mMﬁnalconcentration)wasaddedtotheassay
buffer to prevent N-terminal degradation of GLP-1 during the
assay incubation. HPLC supports the use of radioimmunoas-
says with this speciﬁcity for determination of intact GLP-1 [9].
Because both amidated and glycine-extended forms of GLP-1
are present in the pig [23], C-terminal immunoreactivity was
determined using 2 different antisera (plasma samples for anal-
ysis of the glycine-extended form of GLP-1 were only avail-
able from 3 animals). Antiserum 89390 [75] has an absolute
requirement for the intact amidated C-terminus of GLP-1(7–
36) amide, and cross-reacts 83% with GLP-1(9–36) amide, but
<0.01%withtheglycine-extendedform,GLP-1(7–37),orwith
C-terminallytruncatedfragments.Antiserum92071[75]isspe-
ciﬁc for the C-terminus of GLP-1(7–37) and cross-reacts fully
with GLP-1(9–37) but <0.1% with amidated forms of GLP-1.
Forallassays,theintra-assaycoefﬁcientofvariationwas<6%.
Plasma samples were extracted with 70% ethanol (vol/vol,
ﬁnal concentration) before assay, giving recoveries of 75% for
GLP-1 added to plasma before extraction [54].
The activity of DPPIV in plasma samples was estimated by
the ability to degrade GLP-1(7–37) added to the sample. The
method is based upon the fact that DPPIV is the sole enzyme
responsible for N-terminal degradation of GLP-1 in plasma
[9, 55]. In brief, GLP-1(7–37) (5 µL, 100 fmol) was added
to plasma samples (95 µL), which were then incubated for
1 hour at 37◦C. Samples were put on an ice bath immedi-
ately after incubation and the amount of GLP-1 determined by
an enzyme-linked immunosorbent assay (ELISA) speciﬁc for
N-terminally intact peptide. A reference sample with GLP-1
added to heat-inactivated plasma containing VP (0.01 mM)96 M. O. LARSEN ET AL.
and aprotinin (500 kIU/mL) was processed in parallel. The
DPPIV activity estimate was then calculated as
Activity (%) = (1 − Cunknown/Creference) × 100
where Cunknown and Creference are the calculated concentrations
of the sample and the reference, respectively. The minimum
detectable difference was determined to be 3.2%.
β-Cell Reduction
β-Cell mass was reduced by intravenous administration of
a combination of NIA (Sigma N-3376), 67 mg/kg, and STZ
(Sigma S-0130), 125 mg/kg [37]. Administration of NIA and
STZwasperformedafteran18-hourovernightfastinconscious
animals, and animals were offered SDS fodder 2 hours after
treatment. Animals were observed frequently during the ﬁrst
48hoursafteradministrationofNIAandSTZandbloodglucose
wasmonitoredregularlytoavoidepisodesofhypoglycemiadue
to sudden hyperinsulinemia caused by necrosis of β cells.
Histological Examination of Pancreas
Fixation and Physical Fractionation
After euthanasia with pentobarbitone (20 mL per animal)
(200 mg/mL; Pharmacy of the Royal Veterinary and Agricul-
turalUniversity,Copenhagen,Denmark)attheendofthestudy
period, the pancreas was isolated in toto for histological ex-
amination as previously described [37]. Histological exami-
nation was performed 41 ± 21 days (range 21 to 60) after
NIA + STZ dosing in all animals and compared with data
from normal, age-matched animals (n = 5). In short, pancreata
wereﬁxedinparaformaldehyde(Bie&Berntsen,Copenhagen,
Denmark), embedded in 3% agar solution (catalogue number
303289,Meco-Benzon,Copenhagen,Denmark),andsectioned
as practiced in the smooth fractionator method [5, 40]. The de-
parafﬁnized sections were stained for insulin and a mixture of
antibodies to glucagon, somatostatin, and pancreatic polypep-
tide to visualize β and non-β endocrine cells.
Furthermore, sections were counterstained with Mayer’s
hematoxyline. Mass of β and non-β endocrine cells was eval-
uated stereologically in 2 to 3 sections with the origin of the
sections blinded to the observer. Mass of endocrine cells is ex-
pressed at mg/kg body weight.
Formulation of Compounds
VP (purity >98%) was synthesized by Dr. L. Christiansen,
Novo Nordisk A/S, and was dissolved in physiological saline
less than 60 minutes prior to administration. NIA was weighed
out in individual portions and protected from light, and was
dissolved in sterile saline (0.9%; SAD) to a concentration of
300 mg/mL immediately before injection. STZ was weighed
out in individual portions and dissolved in sodium citrate
buffer (catalogue number 929546), Bie & Berntsen), pH =
4.7, to a concentration of 62.5 mg/mL immediately before
injection.
Evaluation
Effects of VP on glucose tolerance and hormone levels were
evaluated based on changes in postprandial plasma concentra-
tions of glucose, insulin, and glucagon, as well as intact and
total GLP-1 and GIP. Data are presented as mean ± SD.
The area under curve (AUC) for total and intact forms
of the GLP-1 and GIP was calculated using the trapezoidal
method (baseline = 0). For each incretin hormone, the per-
centage of intact peptide was expressed as AUCN-terminal rel-
ative to AUCC-terminal. The glucose excursion and amounts of
insulin secreted in response to the oral glucose load are ex-
pressed as incremental AUC, calculated after subtraction of the
basal concentrations measured in samples taken before the glu-
cose load. The insulinogenic index was calculated by dividing
the incremental AUC for insulin by the incremental AUC for
glucose during the postprandial period (0 to 240 minutes). All
calculationsandstatisticalevaluationofresultswereperformed
usingpaired2-tailedStudent’st testand1-wayanalysisofvari-
ance(ANOVA)usingExcel(2000)andGraphPadPrismversion
3.00 for Windows (GraphPad Software, San Diego, California,
USA). P values of .05 or less were considered signiﬁcant.
RESULTS
Effects of NIA and STZ
Administration of NIA and STZ induced a signiﬁcant
increase in fasting plasma glucose without signiﬁcant changes
infastingplasmavaluesofinsulin(Table1).Furthermore,there
werenosigniﬁcantchangesinfastingplasmalevelsofanyofthe
measured forms of GLP-1 and GIP or plasma DPPIV activity.
Administration of NIA and STZ induced a signiﬁcant in-
crease in AUCglucose after the OGTT, but no signiﬁcant changes
wereseeninAUCinsulin (Table2).However,althoughAUCinsulin
was not signiﬁcantly decreased, the insulin response after NIA
+ STZ was somewhat delayed and diminished compared to
normal animals (Figure 1), with the ratio of insulin to glucose
at 30 minutes being signiﬁcantly reduced after NIA + STZ
(22 ± 3 versus 51 ± 23; P < .02). Neither the absolute in-
cretin concentrations nor the proportions of intact relative to
total forms of GLP-1 and GIP were altered by NIA + STZ
treatment (Table 3) (Figures 2 and 3), and DPPIV activity was
not affected (Figure 4) (data on DPPIV activity are normalized
according to baseline values in Figure 4 in order to illustrate
the change in individual animals better).INHIBITION OF DPPIV NORMALIZES GLUCOSE TOLERANCE 97
TABLE 1
Fasting level of parameters before and after dosing of NIA (67 mg/kg) and STZ (125 mg/kg) in male G¨ ottingen minipigs
Plasma
glucose
(mM)
Plasma
insulin
(pM)
N-terminal
GLP-1
(pM)
C-terminal
amidated
GLP-1 (pM)
C-terminal
glycine-extended
GLP-1 (pM)
N-terminal
GIP (pM)
C-terminal
GIP (pM)
Before dosing 3.6 ± 0.2 36 ± 6 12.3 ± 8.0 4.3 ± 3.2 9.9 ± 1.0 4.3 ± 1.8 7.6 ± 4.8
After dosing 4.8 ± 1.3 41 ± 21 13.1 ± 8.4 2.8 ± 1.7 8.6 ± 4.0 5.9 ± 2.4 17.1 ± 14
P value .05 .45 .80 .43 .68 .14 .08
Note. Data are presented as mean±SD of individual plasma values (n = 6 for all parameters except C-terminal glycine-extended GLP-1,
where n = 3). P values are based on paired Student’s t test.
FIGURE 1
Plasma levels of glucose (A, C) and insulin (B, D) during OGTT in male G¨ ottingen minipigs before (A, B) and after
(C, D) dosing of NIA (6 mg/kg) and STZ (125 mg/kg). Animals are either dosed with VP (50 mg/kg) () or vehicle (). Glucose
(2 g/kg) ingested at t =0 minutes, VP or vehicle dosed IV at t =−15 minutes; n = 6. Note different scales on Y-axis. Data are
mean ± SEM.98 M. O. LARSEN ET AL.
TABLE 2
Values of incremental AUC for glucose and insulin during
OGTT in male G¨ ottingen minipigs
Animals, dosea
Glucose
(mM × min)
Insulin
(pM × min)
Pre, Veh 364 ± 295 30997 ± 26838
Pre, VP 194 ± 129 26950 ± 15010
Post, Veh 677 ± 339 27877 ± 14963
Post, VP 352 ± 179 16875 ± 8050
P (Post, Veh versus Pre, Veh) .05 .64
P (Pre, Veh versus Pre, VP) .08 .78
P (Post, Veh versus Post, VP) .02 .09
Note. Data are presented as mean±SD of individual values (n = 6
for all parameters). P values are based on paired Student’s t test.
aPre=normalanimals;Post=animalsdosedwithNIA(67mg/kg)
+ STZ (125 mg/kg); Veh = vehicle.
FIGURE 2
Plasma levels of intact (N-terminal) () and total (C-terminal) () GLP-1 during OGTT in male G¨ ottingen minipigs before
(A, B) and after (C, D) dosing of NIA (67 mg/kg) and STZ (125 mg/kg). Animals are dosed with either vehicle (A, C)o rV P
(50 mg/kg) (B, D). C-terminal GLP-1 includes both amidated and glycine-extended forms of the peptide. Glucose (2 g/kg)
ingested at t =0 minutes, VP or vehicle dosed IV at t =−15 minutes. Data are presented as mean ± SEM, n = 3.
Based on stereological evaluation, β-cell mass (mg/kg)
(7.02 ± 3.46 versus 17.68 ± 4.67 in normal animals [37]
(P <.001)) was signiﬁcantly reduced in animals dosed with
NIA + STZ, whereas non-β-cell mass (mg/kg) was not
changed (5.59 ± 0.86 versus 4.79 ± 1.30 in normal animals,
nonsigniﬁcant [NS]). The pancreatic islets of animals dosed
with NIA + STZ were found to be highly irregular due to dis-
appearance of a large proportion of the β cells. Furthermore,
there was an apparent increase in small clusters of islet cells
and of single β and non-β cells. No other abnormalities were
discovered during morphological examination of pancreatic
tissues.
Effect of VP Administration
PlasmaDPPIVactivitywassigniﬁcantlyreducedbyVPboth
in normal animals and after NIA + STZ (Table 3, Figure 4);T
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FIGURE 3
Plasma levels of intact (N-terminal) () and total (C-terminal) () GIP during OGTT in male G¨ ottingen minipigs before (A, B)
and after (C, D) dosing of NIA (67 mg/kg) and STZ (125 mg/kg). Animals are dosed with either vehicle (A, C)o rV P
(50 mg/kg) (B, D). Glucose (2 g/kg) ingested at t =0 minutes, VP or vehicle dosed IV at t =−15 minutes. Data are presented as
mean ± SEM, n = 6. Note different scales on Y-axis.
however, there was some variability of the effect of VP on
DPPIV activity in the individual animals, especially before ad-
ministration of NIA + STZ.
VP signiﬁcantly improved glucose tolerance compared to
vehicletreatmentinanimalspreviouslydosedwithNIA+STZ.
Thus AUCglucose was decreased substantially, whereas no sig-
niﬁcant effect was seen in normal animals (Table 2). VP did
not increase insulin levels during the OGTT in either normal
animals or after administration of NIA + STZ, but rather, there
was a tendency for insulin levels to be slightly lower after VP
(althoughthisfailedtoreachstatisticalsigniﬁcance)(Figure1).
In spite of the apparently lower insulin levels after VP, the in-
sulinogenicindexwasincreasedbyVPinnormalanimals(from
83 ± 42 to 192 ± 108; P < .05). This effect of VP was signiﬁ-
cantlylarger(P <.01)thaninanimalsdosedwithNIA+STZ,
where no signiﬁcant insulinogenic effect of VP was seen (45±
23 in vehicle-treated animals versus 57 ± 29 in VP-dosed
animals, NS).
DPPIV inhibition with VP did not affect the total amount
of GIP (GIP AUCC-terminal) released in response to the OGTT
in normal animals, but surprisingly, in the group with reduced
β-cell mass, total GIP levels showed a signiﬁcant reduction
(Table 3, Figure 3). In contrast, concentrations of intact GIP
were elevated by VP in both normal animals and after NIA +
STZ.ThisresultedintheproportionofGIPthatremainedintact
and biologically active being signiﬁcantly increased by VP in
both groups.
Changes in GLP-1 concentrations were less obvious, due in
part to the fact that data on total GLP-1 (amidated + glycine-
extended) were only available for 3 out of the 6 animals. Total
GLP-1 was not affected by VP in either normal pigs or af-
ter NIA + STZ (Table 3, Figure 2). Although they failed toINHIBITION OF DPPIV NORMALIZES GLUCOSE TOLERANCE 101
FIGURE 4
Plasma DPPIV activity during OGTT in male G¨ ottingen minipigs before (A) and after (B) dosing of NIA (67 mg/kg) and STZ
(125 mg/kg). Animals are dosed with either VP (50 mg/kg) () or vehicle (). Glucose (2 g/kg) ingested at t =0 minutes, VP or
vehicle dosed IV at t =−15 minutes; n = 6. Data are presented as mean ± SD and are normalized according to baseline values.
reach statistical signiﬁcance for the group as a whole, intact
GLP-1 levels in individual animals showed a tendency to in-
crease following VP administration, resulting in a trend toward
an increased proportion of intact GLP-1.
Proportion of Glycine-Extended C-Terminal
GLP-1 Compared to Total C-Terminal GLP-1
Both amidated and glycine-extended GLP-1 are present in
the pig. The use of the 2 different C-terminal assays, which are
able to discriminate between the forms, revealed that glycine-
extendedGLP-1isthepredominantforminthepig,accounting
for 74% ± 13% of total GLP-1 in the fasted state and 60%±
4% of total GLP-1 AUCC-terminal in the postprandial state.
Administration of NIA + STZ or VP did not change these
proportions.
DISCUSSION
DPPIV inhibitors are currently under investigation as new
antidiabetic agents. They improve adverse glucose tolerance
in rodents [1, 4, 56, 57, 63] and in type 2 diabetic patients
in the early stages of the disease [2]. Their mechanism of
action is believed to involve enhancement of endogenous in-
cretins, and because of this, it is unknown whether they will
also be effective when insulin secretory capacity is impaired.
This study, therefore, aimed to examine the effect of DPPIV in-
hibitioninamodelofglucoseintoleranceduetoreducedβ-cell
mass. The mild deterioration of glucose tolerance and insulin
response during oral glucose following the modest (to 40%)
β-cell reduction is in accord with human data showing that
a more substantial β-cell reduction (to around 10% to 15%)
is required before overt insulin-dependent diabetes develops
[20, 32, 58].
DPPIV inhibitors structurally based upon the dipeptide
product of DPPIV cleavage, such as VP, ile-thiazolidine, and
NVPDPP728, are effective in vivo, inhibiting plasma DPPIV
activity in pig, man, monkey, rat, and dog [4, 8, 12, 56, 67]. In
this study, VP inhibited plasma DPPIV activity by over 90%
during the OGTT, and was associated with increased levels
of intact GIP. Total GIP levels (C-terminal assay) were unaf-
fected by VP in normal animals, but the decrease seen in the
glucose-intolerant group is in agreement with previous stud-
ies in normal dogs [12]. This was interpreted as reduced se-
cretion of GIP [12], because the metabolic clearance rate of
C-terminal GIP immunoreactivity is unchanged by DPPIV in-
hibition [7]. Enhanced intact GIP levels may feedback to in-
hibit further secretion, directly at the K cells or indirectly via
another agent. In the latter case, insulin can inhibit GIP secre-
tion [62], although in the present study, insulin levels were,
if anything, lower after VP. GLP-1 concentrations were, sur-
prisingly, apparently not affected by VP. However, this ﬁnding
must be interpreted with some caution, because only 3 ani-
mals were available for analysis of total GLP-1 immunoreac-
tivity, and, as noted earlier, there was a tendency for intact
GLP-1 to make up a greater proportion of total GLP-1 follow-
ing VP. Acute DPPIV inhibition prevents N-terminal degra-
dation of exogenous GLP-1 [8], and increases levels of en-
dogenous intact GLP-1 [1, 4, 12, 63]. After chronic DPPIV
inhibition, intact GLP-1 levels increase in some [63], but not
all [56], studies. The reason for these differences is unclear,
and further studies designed to investigate the mechanisms
regulating K- and L-cell activity are needed before the overall102 M. O. LARSEN ET AL.
effectofDPPIVinhibitiononincretinhormonesecretioncanbe
assessed.
Inthepresentstudy,VPreducedthehyperglycemicresponse
to oral glucose in glucose-intolerant animals. However, in con-
trast to results obtained after acute DPPIV inhibition in obese
rodents [1, 4, 63], insulin levels were not increased, but were
actually slightly lower than in vehicle-treated animals. This
could reﬂect the integrated response of the pancreas to 2 si-
multaneous opposing stimuli, i.e., increased insulin secretion
in response to elevated intact incretin hormone levels, together
with a concomitant reduction of insulin secretion due to lower
glucose levels. Indeed, reduced insulin responses to a glucose
or meal challenge after GLP-1 infusion have been reported in
some [22, 46, 49], but not all [65, 71, 74], studies in human
subjects with type 2 diabetes, whereas decreased insulin secre-
tory responses to GLP-1 have been observed in humans with
impaired glucose tolerance compared to normal subjects [18].
However, other mechanisms may also contribute. In healthy
subjects, a low GLP-1 infusion rate (0.4 pmol/kg/min) delayed
gastricemptying,therebyreducingtheglycemicexcursionand,
consequentially,insulinsecretion,leadingtotheconclusionthat
thegastricemptyingeffectsmayoutweightheinsulinotropicef-
fects of GLP-1 [49]. Thus, even minor increases in endogenous
intact GLP-1 in the present study may have inﬂuenced gastric
emptying. However, mechanisms other than GLP-1–mediated
effects must also be involved, because glucose tolerance is im-
proved by DPPIV inhibition in mice with a speciﬁc deletion
of the GLP-1 receptor [39]. GIP is one possibility, and the in-
creased intact GIP levels found in the present study may have
contributed to the effective uptake of glucose [44, 51, 52, 73].
Afteron-goingDPPIVinhibition,improvementsinglucosetol-
eranceareassociatedwithareductionininsulinemia[2,56,63],
which indirectly suggest an improvement in insulin sensitivity,
and this is further supported by direct assessment of insulin
sensitivity in glucose-intolerant rats after 12 weeks of DPPIV
inhibition[57].Inthepresentstudy,theinsulinogenicindex(de-
scribing insulin levels relative to glycemia), used as a measure
of β-cell sensitivity to prevailing glucose concentrations, was
increased in normal animals, although this was not seen after
NIA + STZ, possibly because of reduced residual insulin se-
cretory capacity in these animals. Similar improvements in the
insulinogenic index and insulin sensitivity are seen following
long-term (6 weeks) continuous treatment with GLP-1 [74]. It
is also likely that levels of other, as yet unidentiﬁed, substrates
of DPPIV are enhanced, or that products of DPPIV action are
reduced,byVPandmayadditionallycontributetotheimprove-
ments in glucose tolerance.
In conclusion, these studies support the potential use of DP-
PIV inhibitors as an approach to the treatment of adverse post-
prandial glucose where this is attributable to reduced β-cell
mass. Taken together with observations that DPPIV inhibitors
also reduce postprandial glycemia in hyperinsulinemic models
of glucose intolerance [4, 56, 57], the data suggest that DPPIV
inhibition may provide effective treatment of type 2 diabetes,
irrespective of the etiology of the disease.
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